A Comparison of the Effectiveness of Asthma Medications on Asthma Exacerbations in Real World National Cohort

References

• Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021. Executive summary and rationale for key changes. Arch Bronconeumol. 2022;58(1):35–51. doi:10.1016/j.arbres.2021.10.003
   PubMed Web of Science ®Google Scholar
• El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med. 2017;17(1):31. doi:10.1186/s12890-016-0348-4
   PubMed Web of Science ®Google Scholar
• Shepherd J, Rogers G, Anderson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess. 2008;12(19):iii–iv, 1–360. doi:10.3310/hta12190
   Web of Science ®Google Scholar
• Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–336. doi:10.1056/NEJM200008033430504
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730. doi:10.1183/13993003.02730-2021
   PubMed Web of Science ®Google Scholar
• Barnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60(3):455–468. doi:10.4187/respcare.03200
   PubMed Web of Science ®Google Scholar
• Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017;4:CD012226. doi:10.1002/14651858.CD012226.pub2
   PubMed Web of Science ®Google Scholar
• Choi JY, Yoon HK, Lee JH, et al. Current status of asthma care in South Korea: nationwide the health insurance review and assessment service database. J Thorac Dis. 2017;9(9):3208–3214. doi:10.21037/jtd.2017.08.109
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim SR, Kim S, et al. Impact of the asthma quality assessment program on burden of asthma. J Allergy Clin Immunol Pract. 2021;9(1):419–425 e416. doi:10.1016/j.jaip.2020.08.038
   PubMed Web of Science ®Google Scholar
• Choi JY, Yoon HK, Lee JH, et al. Nationwide pulmonary function test rates in South Korean asthma patients. J Thorac Dis. 2018;10(7):4360–4367. doi:10.21037/jtd.2018.06.109
   PubMed Web of Science ®Google Scholar
• Wang K, Tian P, Fan Y, Wang Y, Liu C. Assessment of second-line treatments for patients with uncontrolled moderate asthma. Int J Clin Exp Med. 2015;8(10):19476–19480.
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1473–1484. doi:10.1001/jama.2018.2757
   PubMed Web of Science ®Google Scholar
• Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 Pt 2):S434–439. doi:10.1016/s0091-6749(98)70155-1
   PubMed Web of Science ®Google Scholar
• Fuller R, Johnson M, Bye A. Fluticasone propionate–an update on preclinical and clinical experience. Respir Med. 1995;89(Suppl A):3–18. doi:10.1016/0954-6111(95)90259-7
   PubMed Web of Science ®Google Scholar
• Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1997;43(2):155–161. doi:10.1046/j.1365-2125.1997.d01-1425.x
   PubMed Web of Science ®Google Scholar
• Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102(4 Pt 2):S36–S51. doi:10.1016/s0091-6749(98)70004-1
   PubMed Web of Science ®Google Scholar
• Adams N, Bestall JM, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma. Cochrane Database Syst Rev. 2002;(1):CD002310. doi:10.1002/14651858.CD002310
   PubMedGoogle Scholar
• Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030. doi:10.1056/NEJMoa1901963
   PubMed Web of Science ®Google Scholar
• Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–928. doi:10.1016/S0140-6736(19)31948-8
   PubMed Web of Science ®Google Scholar
• Rogliani P, Beasley R, Cazzola M, Calzetta L. SMART for the treatment of asthma: a network meta-analysis of real-world evidence. Respir Med. 2021;188:106611. doi:10.1016/j.rmed.2021.106611
   PubMed Web of Science ®Google Scholar
• Okubo K, Baba K. A double-blind non-inferiority clinical study of montelukast, a cysteinyl leukotriene receptor 1 antagonist, compared with pranlukast in patients with seasonal allergic rhinitis. Allergol Int. 2008;57(4):383–390. doi:10.2332/allergolint.O-08-533
   PubMedGoogle Scholar
• Janson SL, McGrath KW, Covington JK, Cheng SC, Boushey HA. Individualized asthma self-management improves medication adherence and markers of asthma control. J Allergy Clin Immunol. 2009;123(4):840–846. doi:10.1016/j.jaci.2009.01.053
   PubMed Web of Science ®Google Scholar
• Choi NK, Shantakumar S, Kim MS, et al. Real-world treatment patterns, outcomes, and healthcare resource utilization in newly treated Korean patients with asthma: a retrospective cohort study. Allergy Asthma Immunol Res. 2022;14(2):220–232. doi:10.4168/aair.2022.14.2.220
   PubMed Web of Science ®Google Scholar
• Small M, Anderson P, Vickers A, Kay S, Fermer S. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28(3):202–212. doi:10.1007/s12325-010-0108-4
   PubMed Web of Science ®Google Scholar
• Virchow JC, Crompton GK, Dal negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–19. doi:10.1016/j.rmed.2007.07.031
   PubMed Web of Science ®Google Scholar
• Ban GY, Kim SC, Lee HY, Ye YM, Shin YS, Park HS. Risk factors predicting severe asthma exacerbations in adult asthmatics: a real-world clinical evidence. Allergy Asthma Immunol Res. 2021;13(3):420–434. doi:10.4168/aair.2021.13.3.420
   PubMed Web of Science ®Google Scholar